These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26386476)

  • 1. Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy.
    Sasso M; Audière S; Kemgang A; Gaouar F; Corpechot C; Chazouillères O; Fournier C; Golsztejn O; Prince S; Menu Y; Sandrin L; Miette V
    Ultrasound Med Biol; 2016 Jan; 42(1):92-103. PubMed ID: 26386476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.
    Sasso M; Beaugrand M; de Ledinghen V; Douvin C; Marcellin P; Poupon R; Sandrin L; Miette V
    Ultrasound Med Biol; 2010 Nov; 36(11):1825-35. PubMed ID: 20870345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan
    de Lédinghen V; Hiriart JB; Vergniol J; Merrouche W; Bedossa P; Paradis V
    Dig Dis Sci; 2017 Sep; 62(9):2569-2577. PubMed ID: 28577247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
    Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H
    Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
    Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
    J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
    de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
    Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
    de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
    J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Jung KS; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
    J Hepatol; 2017 May; 66(5):1022-1030. PubMed ID: 28039099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Ultrasound Attenuation Measurement Method for the Non-invasive Evaluation of Hepatic Steatosis Using FibroScan.
    Audière S; Labourdette A; Miette V; Fournier C; Ternifi R; Boussida S; Pouletaut P; Charleux F; Bensamoun SF; Harrison SA; Sandrin L
    Ultrasound Med Biol; 2021 Nov; 47(11):3181-3195. PubMed ID: 34373137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of controlled attenuation parameter for the noninvasive assessment of liver steatosis.
    Ferraioli G; Tinelli C; De Silvestri A; Lissandrin R; Above E; Dellafiore C; Poma G; Di Gregorio M; Maiocchi L; Maserati R; Filice C
    Liver Int; 2016 Dec; 36(12):1860-1866. PubMed ID: 27439331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.
    Caussy C; Brissot J; Singh S; Bassirian S; Hernandez C; Bettencourt R; Rizo E; Richards L; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1842-1850.e6. PubMed ID: 31843596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic accuracy for alcoholic liver disease with controlled Attenuation Parameter (CAP) measured by transient elastography for the non-invasive assessment of liver steatosis].
    Kikuchi M; Umeda R; Tsuruya K; Shiozawa H; Matsushima M; Abe K; Kikuchi M; Takahashi M; Yamagishi Y; Nishizaki H; Horie Y; Kanai T
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2015 Oct; 50(5):235-47. PubMed ID: 26946784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery.
    Tavaglione F; De Vincentis A; Bruni V; Gallo IF; Carotti S; Tuccinardi D; Spagnolo G; Ciociola E; Mancina RM; Jamialahmadi O; D'Alessio R; Bottazzi B; Manfrini S; Picardi A; Perrone G; Pozzilli P; Caricato M; Vespasiani-Gentilucci U; Romeo S
    Liver Int; 2022 Feb; 42(2):374-383. PubMed ID: 34890093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.
    Wong VW; Petta S; Hiriart JB; Cammà C; Wong GL; Marra F; Vergniol J; Chan AW; Tuttolomondo A; Merrouche W; Chan HL; Le Bail B; Arena U; Craxì A; de Lédinghen V
    J Hepatol; 2017 Sep; 67(3):577-584. PubMed ID: 28506907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort.
    Cardoso AC; Cravo C; Calçado FL; Rezende G; Campos CFF; Neto JMA; Luz RP; Soares JAS; Moraes-Coelho HS; Leite NC; Perez RM; Villela-Nogueira CA
    Eur J Gastroenterol Hepatol; 2020 Feb; 32(2):231-238. PubMed ID: 31464788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.
    Thiele M; Rausch V; Fluhr G; Kjærgaard M; Piecha F; Mueller J; Straub BK; Lupșor-Platon M; De-Ledinghen V; Seitz HK; Detlefsen S; Madsen B; Krag A; Mueller S
    J Hepatol; 2018 May; 68(5):1025-1032. PubMed ID: 29343427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.
    Sasso M; Tengher-Barna I; Ziol M; Miette V; Fournier C; Sandrin L; Poupon R; Cardoso AC; Marcellin P; Douvin C; de Ledinghen V; Trinchet JC; Beaugrand M
    J Viral Hepat; 2012 Apr; 19(4):244-53. PubMed ID: 22404722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
    Petroff D; Blank V; Newsome PN; Shalimar ; Voican CS; Thiele M; de Lédinghen V; Baumeler S; Chan WK; Perlemuter G; Cardoso AC; Aggarwal S; Sasso M; Eddowes PJ; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Cobbold JF; Naveau S; Lupsor-Platon M; Mueller S; Krag A; Irles-Depe M; Semela D; Wong GL; Wong VW; Villela-Nogueira CA; Garg H; Chazouillères O; Wiegand J; Karlas T
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):185-198. PubMed ID: 33460567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.